<html xmlns:mims="http://www.mims.com"><head><link type="text/css" href="css/redmond/jquery-ui-1.8.6.custom.css" rel="stylesheet" /><link type="text/css" href="css/mims.css" rel="stylesheet" /><script type="text/javascript" src="scripts/jquery-1.4.4.min.js"></script><script type="text/javascript" src="scripts/jquery-ui-1.8.6.custom.min.js"></script><script type="text/javascript" src="scripts/monograph.js"></script></head><body><div id="tabs"><ul><li><a href="#tab-generic">Generic</a></li></ul><div id="tab-generic"><h4 class="subheading"></h4><table class="ui-widget monograph"><tr><td class="monograph-heading ui-widget-content"><span style="font-weight: bold">Dosage</span></td><td class="ui-widget-content"><I>Oral</I><BR><B> HIV infection</B><BR><B><I>Adult: </I></B>60: 30 mg; &amp;ge;60 kg: 40 mg. Doses to be taken every 12 hr. <BR><B><I>Child: </I></B>From birth-13 days old: 500 mcg/kg; &amp;ge;14 days old and weighing 30 kg: 1 mg/kg; 30 kg-60 kg: 30 mg; &amp;ge;60 kg: 40 mg. Doses to be taken every 12 hr.  <table border=''1''><tr><td><B>CrCl (ml/min)</B></td><td><B>Dosage Recommendation</B></td></tr><tr><td>26-50</td><td>60 kg: 15 mg; &amp;ge;60 kg: 20 mg. Doses to be taken every 12 hr. </td></tr><tr><td>25</td><td>60 kg: 15 mg; &amp;ge;60 kg: 20 mg. Doses to be taken every 24 hr. </td></tr></table><BR><BR><B><I>Special Populations: </I></B>Reduce dose in patients with renal impairment: CrCl 25-60 mL/min: 20 mg every 12 hrs (patients weighing &amp;ge;60 kg body weight) or 15 mg every 12 hrs (patients weighing 60 kg body weight). CrCl 25 mL/min: 20 mg every 24 hrs (patients weighing &amp;ge;60 kg body weight) or 15 mg every 24 hrs (patients weighing 60 kg body weight).</td></tr><tr><td class="monograph-heading ui-widget-content"><span style="font-weight: bold">Administration</span></td><td class="ui-widget-content">May be taken with or without food.<br></td></tr><tr><td class="monograph-heading ui-widget-content"><span style="font-weight: bold">Contraindications</span></td><td class="ui-widget-content">Hypersensitivity. Lactation.</td></tr><tr><td class="monograph-heading ui-widget-content"><span style="font-weight: bold">Special precautions</span></td><td class="ui-widget-content">Hepatomegaly or other risk factors for liver disease. History of peripheral neuropathy and renal impairment. Pregnancy. Discontinue treatment if peripheral neuropathy develops; may resume treatment at half the previous dose if symptoms resolve upon drug withdrawal. Monitor for signs of pancreatitis. Discontinue treatment if there is a rapid increase in aminotransferase concentrations, progressive hepatomegaly or steatosis, or metabolic or lactic acidosis. Increased risk of severe and fatal hepatic adverse events in patients with chronic hepatitis B or C treated with combination antiretroviral therapy.</td></tr><tr><td class="monograph-heading ui-widget-content"><span style="font-weight: bold">Adverse reactions</span></td><td class="ui-widget-content">Headache, nausea, vomiting, asthenia, chest pain, influenza-like syndrome, insomnia, abdominal pain, anorexia, neutropenia, thrombocytopenia, arthralgia, myalgia, mood changes, dyspnoea, pharyngitis, skin rashes, pruritus.</td></tr><tr><td class="monograph-heading ui-widget-content"><span style="font-weight: bold">Drug interactions</span></td><td class="ui-widget-content">Antiviral effect inhibited by zidovudine, doxorubicin and ribavirin. Avoid concurrent admin with drugs that cause pancreatitis (e.g. IV pentamidine) or peripheral neuropathy (e.g. metronidazole, isoniazid and vincristine). Increased risk of adverse effects such as hepatoxicity, peripheral neuropathy and pancreatitis if used with hydroxycarbamide and didanosine.<BR/></td></tr><tr><td class="monograph-heading ui-widget-content"><span style="font-weight: bold">Mechanism of action</span></td><td class="ui-widget-content">Stavudine is converted intracellularly to the active metabolite stavudine 5''-triphosphate which is then incorporated into the viral DNA by reverse transcriptase resulting in premature ending of the DNA chain elongation.<BR><B>Absorption: </B>Rapidly absorbed from the GI tract after oral admin, food may delay its absorption; peak plasma concentrations within 1 hr.<BR><B>Distribution: </B>Crosses the blood-brain barrier and negligible plasma protein binding.<BR><B>Metabolism: </B>Intracellular; converted to the active antiviral triphosphate.<BR><B>Excretion: </B>Urine (about 40%); 1.5 hr (elimination half-life).</td></tr><tr><td class="monograph-heading ui-widget-content"><span style="font-weight: bold">MIMS Class</span></td><td class="ui-widget-content">Antivirals</td></tr><tr><td class="monograph-heading ui-widget-content"><span style="font-weight: bold">ATC Classification</span></td><td class="ui-widget-content">J05AF04 - stavudine; Belongs to the class of nucleoside and nucleotide reverse transcriptase inhibitors. Used in the systemic treatment of viral infections.<BR></td></tr></table></div></div></body></html>